Benjamin Moxley-Wyles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Benjamin Moxley-Wyles has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Amelia Monks
Institute of Biomedical Engineering (IBME), Department of Engineering Science, University of Oxford, Old Road Campus Research Building Oxford, Oxford, UK
2 shared publications- Andrea Chatrian
Institute of Biomedical Engineering (IBME), Department of Engineering Science, University of Oxford, Old Road Campus Research Building Oxford, Oxford, UK.
2 shared publications - Clare Verrill
University of Oxford
2 shared publications - Jens Rittscher
University of Oxford
2 shared publications - Maryam Haghighat
Queensland University of Technology, Brisbane, QLD, Australia
2 shared publications Alan Aberdeen
Ground Truth Labs, 9400 Garsington Road, Oxford Business Park, Oxford, UK
1 shared publication
Latest Publications
- 3 July 2025
- Published by BMJ in BMJ Leader
- Vol. 10 (1) , 94-97
Beyond the numbers: redefining quality in the boardroom
Senior leaders face significant pressure to demonstrate productivity and meet targets while being subject to scrutiny by regulators. This dual focus can create tensions between achieving targets and maintaining quality. Additionally, leaders contend with financial constraints, staffing shortages and evolving patient demographics. The rapid advancement of technology and growing expectations for personalised care further complicate these challenges. Frequent policy shifts, combined with public and media scrutiny, amplify these pressures, making it essential for leaders to prioritise quality amidst competing demands.
- 3 July 2025
- Published by BMJ in BMJ Leader
- Vol. 10 (1) , 94-97
Beyond the numbers: redefining quality in the boardroom
Senior leaders face significant pressure to demonstrate productivity and meet targets while being subject to scrutiny by regulators. This dual focus can create tensions between achieving targets and maintaining quality. Additionally, leaders contend with financial constraints, staffing shortages and evolving patient demographics. The rapid advancement of technology and growing expectations for personalised care further complicate these challenges. Frequent policy shifts, combined with public and media scrutiny, amplify these pressures, making it essential for leaders to prioritise quality amidst competing demands.
- Open Access
- 20 May 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (9) , 1780-1794
Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies
- 20 May 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (9) , 1780-1794
Open AccessArtificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies
- Open Access
Artificial Intelligence for Advance Requesting of Immunohistochemistry in Diagnostically Uncertain Prostate Biopsies
The use of immunohistochemistry in the reporting of prostate biopsies is an important adjunct when the diagnosis is not definite on haematoxylin and eosin (H&E) morphology alone. The process is however inherently inefficient with delays while waiting for pathologist review to make the request and duplicated effort reviewing a case more than once. In this study, we aimed to capture the workflow implications of immunohistochemistry requests and demonstrate a novel artificial intelligence tool to identify cases in which immunohistochemistry (IHC) is required and generate an automated request. We conducted audits of the workflow for prostate biopsies in order to understand the potential implications of automated immunohistochemistry requesting and collected prospective cases to train a deep neural network algorithm to detect tissue regions that presented ambiguous morphology on whole slide images. These ambiguous foci were selected on the basis of the pathologist requesting immunohistochemistry to aid diagnosis. A gradient boosted trees classifier was then used to make a slide level prediction based on the outputs of the neural network prediction. The algorithm was trained on annotations of 219 immunohistochemistry-requested and 80 control images, and tested by 3-fold cross-validation. Validation was conducted on a separate validation dataset of 212 images. Non IHC-requested cases were diagnosed in 17.9 minutes on average, while IHC-requested cases took 33.4 minutes over multiple reporting sessions. We estimated 11 minutes could be saved on average per case by automated IHC requesting, by removing duplication of effort. The tool attained 99% accuracy and 0.99 Area Under the Curve (AUC) on the test data. In the validation, the average agreement with pathologists was 0.81, with a mean AUC of 0.80. We demonstrate the proof-of-principle that an AI tool making automated immunohistochemistry requests could create a significantly leaner workflow and result in pathologist time savings.
Open AccessArtificial Intelligence for Advance Requesting of Immunohistochemistry in Diagnostically Uncertain Prostate Biopsies
The use of immunohistochemistry in the reporting of prostate biopsies is an important adjunct when the diagnosis is not definite on haematoxylin and eosin (H&E) morphology alone. The process is however inherently inefficient with delays while waiting for pathologist review to make the request and duplicated effort reviewing a case more than once. In this study, we aimed to capture the workflow implications of immunohistochemistry requests and demonstrate a novel artificial intelligence tool to identify cases in which immunohistochemistry (IHC) is required and generate an automated request. We conducted audits of the workflow for prostate biopsies in order to understand the potential implications of automated immunohistochemistry requesting and collected prospective cases to train a deep neural network algorithm to detect tissue regions that presented ambiguous morphology on whole slide images. These ambiguous foci were selected on the basis of the pathologist requesting immunohistochemistry to aid diagnosis. A gradient boosted trees classifier was then used to make a slide level prediction based on the outputs of the neural network prediction. The algorithm was trained on annotations of 219 immunohistochemistry-requested and 80 control images, and tested by 3-fold cross-validation. Validation was conducted on a separate validation dataset of 212 images. Non IHC-requested cases were diagnosed in 17.9 minutes on average, while IHC-requested cases took 33.4 minutes over multiple reporting sessions. We estimated 11 minutes could be saved on average per case by automated IHC requesting, by removing duplication of effort. The tool attained 99% accuracy and 0.99 Area Under the Curve (AUC) on the test data. In the validation, the average agreement with pathologists was 0.81, with a mean AUC of 0.80. We demonstrate the proof-of-principle that an AI tool making automated immunohistochemistry requests could create a significantly leaner workflow and result in pathologist time savings.